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 ABSTRACT 
Cardiovascular diseases caused by atherosclerosis are a leading cause of mortality worldwide. 
Inflammation has been described as a key component in the development of atherosclerosis. Lipoxin 
A4 (LXA4) is a lipid mediator derived from arachidonic acid, which has anti-inflammatory and pro-
resolution properties mediated through the FPR2/ALX receptor. This receptor is however, not 
specific to LXA4 and can transduce pro-inflammation or pro-resolution effects depending on the 
different ligands present in the atherosclerotic milieu. 
The aim of the present thesis was to unravel the role of FPR2/ALX signaling in the 
atherosclerotic vascular wall. In addition, the effects of LXA4 were examined with 2 goals: to assess 
the use of LXA4 as possible therapeutic option in mouse models of atherosclerosis, and to elucidate if 
LXA4 effects were mediated through FPR2/ALX signaling. To this end, in vivo, in vitro and ex vivo 
experiments were used to evaluate the role of the FPR2/ALX receptor in human samples of 
atherosclerosis and in mice either expressing or lacking the murine homologue of the FPR2/ALX 
receptor (Fpr2).  
It was discovered that macrophages, smooth muscle cells and endothelial cells in human 
atherosclerotic lesions expressed FPR2/ALX and it was up-regulated by pro-inflammatory stimuli in 
human monocytes in vitro. In three different mouse models, Fpr2 deletion resulted in decreased 
atherosclerosis. Macrophages derived from Fpr2 knock-out mice exhibited reduced inflammation and 
Fpr2 knock-out mice exhibited endothelial dysfunction. 
Finally, treatment with the aspirin-triggered LXA4 (ATL, a LXA4 analogue) significantly 
reduced atherosclerosis, smooth muscle cell migration in vitro and intimal hyperplasia after carotid 
ligation in vivo. Since this effect was absent in Fpr2 knock-out mice, it supports that Fpr2 transduces 
anti-inflammatory signaling in response to this lipid mediator.  
In summary, the results of the present thesis suggest a dual role for FPR2/ALX signaling in 
atherosclerosis, with pro-inflammatory property as the disease develops; whereas anti-inflammatory 
signaling was induced by LXA4. In addition, it was discovered that Fpr2 signaling induced 
differential effects on different cell types within the atherosclerotic lesion.  
In conclusion, FPR2/ALX signaling is present in major cells of the vascular wall and is crucial 
for atherosclerosis development. LXA4 is signaling through FPR2/ALX and this supports the use of 
LXA4 as a therapeutic option in atherosclerosis as well as restenosis. 
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ABSTRACT 
Cardiovascular diseases caused by atherosclerosis are a leading cause of mortality 
worldwide. Inflammation has been described as a key component in the development of 
atherosclerosis. Lipoxin A4 (LXA4) is a lipid mediator derived from arachidonic acid, which has 
anti-inflammatory and pro-resolution properties mediated through the FPR2/ALX receptor. This 
receptor is however, not specific to LXA4 and can transduce pro-inflammation or pro-resolution 
effects depending on the different ligands present in the atherosclerotic milieu. 
The aim of the present thesis was to unravel the role of FPR2/ALX signaling in the 
atherosclerotic vascular wall. In addition, the effects of LXA4 were examined with 2 goals: to 
assess the use of LXA4 as possible therapeutic option in mouse models of atherosclerosis, and to 
elucidate if LXA4 effects were mediated through FPR2/ALX signaling. To this end, in vivo, in 
vitro and ex vivo experiments were used to evaluate the role of the FPR2/ALX receptor in human 
samples of atherosclerosis and in mice either expressing or lacking the murine homologue of the 
FPR2/ALX receptor (Fpr2).  
It was discovered that macrophages, smooth muscle cells and endothelial cells in human 
atherosclerotic lesions expressed FPR2/ALX and it was up-regulated by pro-inflammatory 
stimuli in human monocytes in vitro. In three different mouse models, Fpr2 deletion resulted in 
decreased atherosclerosis. Macrophages derived from Fpr2 knock-out mice exhibited reduced 
inflammation and Fpr2 knock-out mice exhibited endothelial dysfunction. 
Finally, treatment with the aspirin-triggered LXA4 (ATL, a LXA4 analogue) significantly 
reduced atherosclerosis, smooth muscle cell migration in vitro and intimal hyperplasia after 
carotid ligation in vivo. Since this effect was absent in Fpr2 knock-out mice, it supports that Fpr2 
transduces anti-inflammatory signaling in response to this lipid mediator.  
In summary, the results of the present thesis suggest a dual role for FPR2/ALX signaling in 
atherosclerosis, with pro-inflammatory property as the disease develops; whereas anti-
inflammatory signaling was induced by LXA4. In addition, it was discovered that Fpr2 signaling 
induced differential effects on different cell types within the atherosclerotic lesion.  
In conclusion, FPR2/ALX signaling is present in major cells of the vascular wall and is 
crucial for atherosclerosis development. LXA4 is signaling through FPR2/ALX and this supports 
the use of LXA4 as a therapeutic option in atherosclerosis as well as restenosis. 
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1 Introduction 
1.1 The vascular wall  
The vascular wall is organized in three different layers: intima, media and adventitia. The 
inner layer, closest to the lumen, contains the endothelial cells (ECs), which are crucial for 
homeostasis and cell recruitment. Once the EC is activated, adhesion molecules are expressed 
and induce the recruitment of leukocytes from the blood stream. These leukocytes can go to the 
adjacent tissues or remain within the vessel wall, mainly in the intima. The media is 
predominantly composed by smooth muscle cells (SMC) with contractile properties, which gives 
the vascular tone. The SMC population can be divided into two phenotypes: the contractile 
phenotype with high amounts of different actins in the cytoplasm and very limited proliferation 
properties; and the synthetic phenotype with less contractile ability and increased proliferation 
rate [1]. The outer layer of the arterial wall is the adventitia, a collagen-rich connective tissue 
matrix containing fibroblasts, nerve fibers, and immune cells such as mast cells, macrophages 
and lymphocytes. 
1.2 Atherosclerosis 
Cardiovascular diseases (CVD), such as ischemic heart disease and stroke, are the leading 
cause of mortality in western developed countries. Besides the increased mortality, around 30% 
of all disability in European Union is CVD-related. The costs as a result of CVD are estimated to 
almost 196 billion Euros spent every year [2], which illustrates the large impact CVD has in the 
society. The underlying cause of coronary artery and cerebrovascular disease is atherosclerosis. 
This chronic disease is characterized by the accumulation of lipids and inflammatory cells within 
the vessel wall. 
1.2.1 Initiation 
The early stages of atherosclerosis are characterized by the deposition of low density 
lipoproteins (LDL) within the intima [3], leading to EC activation and recruitment of leukocytes 
[4]. LDL can be oxidized by for example direct oxidation or lipoxygenase activity. The oxidized 
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LDL (oxLDL) is then taken up by macrophages, leading to the formation of foam cells, which 
are the main cells in atherosclerotic lesions [5]. 
The main immune cells that ingress from the bloodstream to the atherosclerotic lesions are: 
monocytes/macrophages [6], neutrophils [7], dendritic cells [8], T and B cells [9]. The ingress of 
leukocytes promotes inflammation, which alters the homeostatic state of the vascular wall 
components. Furthermore, the cells interact with each other, which further enhances the 
inflammatory process and creates a vicious circle by which the inflammatory milieu keeps the EC 
activated and recruits more cells from the blood stream. 
1.2.2 Progression 
Several pro-inflammatory cytokines, such as interleukin (IL)-1, tumor necrosis factor 
(TNF)- [10] and IL-6 [11] contribute to the continued immune stimulation in atherosclerotic 
lesions, leading to chronic inflammation. In addition to these proteins, activation of enzymes that 
oxidize lipids will lead to the formation of lipid mediators of inflammation, which further 
enhance inflammatory reactions through specific receptors [12].  
Initially, the resolution of inflammation was believed to be a passive phenomenon, due to 
the reduction of inflammatory stimulation. Recent knowledge has however shown that specific 
pro-resolution mediators can act as “stop-signals” for inflammation, promoting the ending of 
inflammation and subsequently healing [13]. In other words, to achieve healing after 
inflammation is induced, an active resolution process needs to take place. It is now widely 
accepted that there is a failure in the resolution of vascular inflammation during plaque 
progression and the persistence of the inflammation [14]. For example, IL-10 and transforming 
growth factor (TGF)- have been suggested as anti-inflammatory mediators, that act by limiting 
inflammation within atherosclerotic lesions [10]. Likewise, specific lipid mediators are also 
involved in the resolution of inflammation.  
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Along with the accumulation of immune cells and inflammatory mediators, also growth 
factors are produced and released within the atherosclerotic lesion. This environment will 
stimulate SMCs to migrate from the media to the intima [15] and increase their proliferation rate 
[16]. As the plaque progresses, cell death [17], and production of free radicals [18] will further 
increase the inflammatory process, promoting neoangiogenesis within the plaque and the 
formation of a necrotic core. In addition, the formation of a fibrous cap composed of SMCs and 
collagen will protect the plaque content to be exposed to the blood stream [19]. 
In advanced atherosclerotic lesions, the inflammatory process is associated with the 
accumulation of dead cells [20]. This accumulation can be due to either an increased apoptosis 
within the plaque [21] or to a lack of clearance of apoptotic cells, also known as efferocytosis 
[20]. The latter is a hallmark of the resolution of inflammation, and the lack of efferocytosis has 
been associated with increased atherosclerosis [22]. 
1.2.3 Unstable plaques 
As mentioned above, the atherosclerotic plaque is covered by a fibrous cap consisting of 
SMCs and collagen. Although the trigger remains not fully understood, the onset of collagen 
break-down and SMC death will lead to a weakening of the fibrous cap. Several enzymes have 
been implicated in this process, of which the matrix metalloproteinase (MMP) family of 
proteases is the most studied [23]. For example, MMP-13 is the most abundant and the 
predominant enzyme that is associated with plaque collagen degradation in murine models of 
atherosclerosis [24]. 
Another contributing factor is the appearance of intraplaque hemorrhage [25]. In the latter 
process, neutrophils produce a number of proteases that further increase the extracellular matrix 
(ECM) degradation [7]. As a result, the fibrous cap is degraded, and the atherosclerotic lesion 
becomes unstable, indicating that it is prone to rupture.  
1.2.4 Plaque rupture 
When the fibrous cap of the atherosclerotic plaque ruptures, the inner content of the 
atheroma is exposed to the circulating blood. The exposure of the collagen under the EC layer 
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will promote platelet activation and coagulation, leading to the formation of a thrombus [26]. 
This clot may obstruct the lumen of the blood vessel hence leading to occlusion of blood flow 
depriving the brain or the heart of oxygen, leading to stroke or myocardial infarction, 
respectively. In addition, parts of the atheroma and/or thrombus may produce an embolism and 
obstruct a distal smaller artery. 
1.2.5 Diagnosis 
At initial stages atherosclerosis is asymptomatic and should be suspected when risk 
factors are found. Carotid artery atherosclerosis can be detected by means of an ultrasound. This 
examination can reveal if atherosclerotic plaques are present or not, and determine the degree of 
obstruction of the vessel. In addition, the intima-media thickness (IMT) can be measured. The 
IMT indicates the thickening of the arterial wall and has been associated with an increased 
cardiovascular risk [27, 28]. 
Coronary atherosclerosis can be diagnosed by angiography, in which the administration 
of contrast media will reveal the degree of obstruction or stenosis that the atherosclerotic lesion 
causes of the vascular lumen. Likewise, a transthoracic Doppler echocardiography of the left 
anterior descending coronary artery can give information of reduced coronary flow [29]. Also in 
the diagnosis of both cerebrovascular and coronary atherosclerotic lesions, computerized 
tomography angiography can be used, just to mention a few methods to assess atherosclerotic 
plaques.  
In all the above-mentioned methodologies, the definition of a significant lesion relies on 
the degree of vascular obstruction. However, these diagnostic measures do not distinguish stable 
from unstable lesions. Importantly, plaques not causing either anatomical lumen obstruction or 
hemodynamically significant flow restriction may however be prone to rupture [29], and studies 
are ongoing how to obtain imaging modalities that can identify unstable atherosclerotic lesions. 
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1.2.6 Management 
 
1.2.6.1 Medical treatment 
The management of atherosclerotic vessel disease relies on three different approaches, 
namely lifestyle changes, medical treatments and invasive procedures. In addition, management 
of co-morbidities are important, for example dyslipidemia, diabetes, high blood pressure just to 
mention a few. 
The medical treatment applied in the context of atherosclerosis may impact the process of 
disease. For example, lipid management with the aim to improve lipid profiles in terms of 
reducing LDL and increasing HDL, has shown convincing beneficial effects in patients with 
CVD [30]. Although statins have been suggested to exhibit some anti-inflammatory properties, 
the beneficial effects of this class of drugs are mainly due to their effects on lipids. Low dose 
aspirin is also used in the management of CVD to inhibit platelet aggregation [31]. Again, the 
effect of aspirin in CVD is mainly due to platelet inhibition rather than anti-inflammatory effects. 
Drugs targeting inflammation that are widely used in inflammatory diseases such as rheumatic 
diseases, for instance, methotrexate, colchicine, allopurinol among others has been shown to 
reduce CVD events in epidemiologic or animal studies, and randomized controlled trials are 
ongoing to evaluate the effects of specific anti-inflammatory treatments on cardiovascular risk 
[30].  
1.2.6.2 Angioplasty and restenosis 
Obstructive atherosclerotic lesions as well as vascular occlusions following plaque 
rupture can be treated invasively. In coronary atherosclerosis, percutaneous coronary 
interventions (PCI) are performed by catheter-based balloon dilatation and/or placement of a 
vascular mesh called stent [32]. After this process, vascular SMCs increase proliferation and 
migration, as well as ECM remodeling [33]. This process may result in the formation of an intra-
stent intimal hyperplasia causing restenosis of the coronary vessel [34]. To overcome this 
problem, stents coated with anti-proliferative agents were introduced [35], which reduced the 
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incidence of in-stent restenosis. However, a concern about increased thrombotic events using 
drug-eluting stents has been raised [36]. This reinforces the importance of a better understanding 
of how the vascular wall reacts to injury for improved therapeutic options. 
1.2.7 Mouse models of atherosclerosis 
Hyperlipidemic mice, such as Apolipoprotein E (ApoE-/-) and LDL receptor (Ldlr-/-) 
knock-out mice are widely used models of atherosclerosis. Whereas ApoE-/- mice develop a 
spontaneous atherosclerosis, administration of high fat diet (HFD) is needed in Ldlr-/- mice. The 
advantages of using these mouse models are mainly four: (1) Atherosclerosis development is 
similar to humans. (2) The mouse genome has been described, opening the options to create 
directed knock out (deletion) of a specific gene, hence disrupting its expression or its activity. (3) 
The possibility to apply drugs that block enzymes or receptors. (4) Mice require small space and 
reproduce fast making it possible to handle colonies in small spaces. 
1.3 Lipoxygenases 
1.3.1 Lipid mediator biosynthesis 
There are three main classes of lipoxygenases (LOs) in humans: 5-, 12- and 15-LO. The 
number identifies the carbon atom of the fatty acid that is oxidized by these enzymes. LOs may 
participate in the LDL oxidation during atherosclerosis initiation [37]. Importantly, LO 
metabolism of polyunsaturated fatty acids (PUFA) will yield a series of bioactive lipid mediators, 
with important function within the vascular wall. For example, 5-LO metabolism of the omega 
(-6 PUFA arachidonic acid (AA) will yield the inflammatory mediators leukotrienes (LTs) 
[38]. 5-LO together with the 5-LO activating protein (FLAP) lead to formation of the unstable 
LTA4. Through subsequent enzymatic steps, LTA4 is either converted to LTB4 or conjugated 
with glutathione to form the cysteinyl-LTs (CysLT, LTC4, LTD4, and LTE4). These lipid 
mediators induce leukocyte recruitment and activation, and in addition, regulate critical functions 
of the vascular wall, such as endothelial permeability [40] and vascular tone [41, 42].  
In contrast, AA is also the substrate for the anti-inflammatory and pro-resolving lipoxin A4 
(LXA4) [39]. The biosynthesis of LXA4 requires sequential dual lipoxygenation involving all 
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three different classes of lipoxygenases: 5-LO, 12-LO and 15-LO (Figure 1). Since these 
enzymes exhibit a differential cellular expression pattern, LXA4 biosynthesis may involve trans-
cellular metabolism. In brief, a donor cell transforms the PUFA into an intermediate and release 
it, and an acceptor cell, expressing another enzymatic step, collects this intermediate and 
metabolizes it into the bioactive molecule [43]. For example, the formation of LTA4 via the 5-LO 
pathway takes place mainly in myeloid cells [39], and platelets that are rich in 12-LO are able to 
collect LTA4 and transform it to LXA4 [44] (Figure 1). As a consequence, although platelets 
cannot form LXA4 by themselves, they are the main source of LXA4 in vivo [44]. 
The 15-epimer of LXA4, a more stable LXA4 analogue with the same pro-resolving 
properties, can be formed by the acetylation of the cyclooxygenase 2 (COX2) enzyme by aspirin. 
This leads to 15(R)-HETE formation, which can be further processes by 5-LO leading to 15-epi-
LXA4 (Figure 1). Since 15-epi-LXA4 is produced only in the presence of aspirin, it is also known 
as aspirin triggered lipoxin (ATL).  
Likewise, LO metabolism of 3 PUFA, leads to the formation of lipid mediators with 
mainly anti-inflammatory properties, such as resolvins (Rv), protectins (PD) and maresins 
(MaR), which participate in the resolution of inflammation [13].  
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Figure 1: Lipoxin biosynthesis. 
The figure represents the different enzymes that metabolize arachidonic acid into lipoxin A4 (LXA4) and aspirin-
triggered 15-epi LXA4 (ATL); 5-lipoxygenase (LO), 12-LO and 15-LO or cyclooxygenase 2 (COX2). Both LXA4 
and ATL are known to bind to the FPR2/ALX receptor. 
 
The differential effects (pro-inflammation and pro-resolution) of the different LO-derived 
lipid mediators have led to the hypothesis that their role in inflammation can be divided into 3 
phases, as depicted in Figure 2. The initiation is where the insult happens and many pro-
inflammatory lipid mediators are produced. The resolution phase is when the insult is absent; a 
lipid switch takes place by the increase in pro-resolving lipid mediator and a reduction of pro-
inflammatory mediators, which act as “stop signals”. Finally, the termination phase is where the 
healing is concluded and the tissue goes back to homeostasis. 
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Figure 2. Resolution of inflammation 
The resolution is divided in 3 phases: During initiation there is an increase in pro-inflammatory mediators, such as 
leukotriene B4 (LTB4). Subsequently, resolution starts as the levels of the pro-resolution lipid mediators increase, for 
example lipoxin A4 (LXA4), resolvin D1 and E1 (RvD1 and RvE1), and the levels of pro-inflammatory lipid 
mediators decrease, which is referred to as the “lipid switch”. The pro-resolution lipid mediators promote a “stop 
signal” which leads to the third and last phase, the termination of inflammation. Adapted from Bosma-Den Boer, 
Nutrition & Metabolism 2012 [45] 
 
1.3.2 Lipoxygenases in CVD 
Human studies in CVD have shown associations of genetic variations in the 5-LO 
promoter with subclinical atherosclerosis [46], the presence of leukotriene receptors in human 
atherosclerotic lesions [47] and leukotrienes as biomarkers of atherosclerosis [48]. In addition, a 
main source of knowledge about the role of LOs in CVD has emerged from mouse models. As 
mentioned above, these enzymes are important for the production of lipid mediators with effects 
on both inflammation and resolution, which could offer an explanation as to the contradictory 
results obtained in different studies.  
For example, Ldlr-/- mice heterozygous for 5-LO (5-LO-/+) exhibited 95% inhibition of 
atherosclerosis [49]. However, subsequent studies failed to repeat those findings in either 
homozygous or heterozygous 5-LO deletion in both ApoE-/- and Ldlr-/- mice and reported neutral 
effects on atherosclerosis [50, 51]. It is important to take into consideration that genetic targeting 
of 5-LO will disrupt the formation of all 5-LO-derived lipid mediators. In contrast, BAYx1005, 
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which is an antagonist of the 5-LO activating protein (FLAP), inhibited LT synthesis but 
increased LX formation [52]. This suggests that FLAP is a specific target of LT biosynthesis, and 
hyperlipidemic mice treated with BAYx1005 exhibit decreased atherosclerosis [53, 54]. 
Nevertheless, although a subsequent study supported that FLAP is obligatory for LT, but not LX 
production [55], a recent study claimed LX biosynthesis to be dependent on FLAP [56]. 
On the other hand, the 12- and 15-LO are necessary for LXA4 formation from AA (Figure 
1), and genetic targeting of this enzyme blocked LX formation in a murine model of rheumatoid 
arthritis [57]. However, 12/15-LO deletion in hyperlipidemic mice has also generated 
contradictory results. Most studies point to protection against atherosclerosis after 12/15-LO 
knock-out (Table 1) which has been proposed to be due to LDL oxidation by 12/15-LO [37]. 
Likewise, overexpession of human 15-LO under the preproendothelin promoter, to generate a 
vascular wall-specific transgene, increased atherosclerosis in Ldlr-/- mice [58]. However, one 
study reported accelerated atherosclerosis in ApoE-/- x 12/15-LO-/- mice, which was mimicked by 
bone marrow transplantation (BMT), and interestingly, pro-resolution mediators, such as LXA4 
and RvD1 were increased [59]. Also, macrophage-specific overexpression of either human 15-
LO in hyperlipidemic rabbits or murine 12/15-LO in ApoE-/- mice is atheroprotective and 
associated with increased LXA4 formation [59, 60].  
Gender Genotype Diet Time on diet 
Aortic 
root 
En 
Face 
Comments Ref 
M & F ApoE-/- Chow 22 w ↑ ↑ - [59] 
NA ApoE-/- Chow 15 w and 52 w   - [61] 
M & F Ldlr-/- Western 
3, 6, 9, 12 and 
18 w 
  - [62] 
M & F Ldlr-/- Chow 15 w and 32 w NA  
Reduced in males and no 
differences in females. 
[63] 
M & F ApoE-/- Chow+vit E 12 w NA  - [64] 
M & F ApoE-/- Chow 25 w   
Reduced in females and no 
differences in males 
[65] 
Table 1. Effect of 12/15-LO disruption in mouse models of atherosclerosis.  
The table describe different studies using mice lacking 12/15-LO in atherogenic background evaluated at the aortic 
root and en face. 
M= males, F= females; w= weeks; NA= Not available 
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Taken together, those studies illustrates the complexity of studing the 12/15-LO pathway in 
experimental atherosclerosis. Therefore, studying the receptors activated by the respective lipid 
mediators may be an appropriate means of obtaining insight into the role of these bioactive lipids 
in atherosclerosis. For example, in support of the pro-inflammatory role of LTs, either genetic or 
pharmacological targeting of the BLT1 receptor for LTB4 reduces atherosclerosis [66] and intimal 
hyperplasia after vascular injury [47, 67]. 
1.3.3 The possible role of Lipoxin A4 in the vascular wall 
 
As mentioned above, LXA4 has been described as an anti-inflammatory and pro-resolving 
mediator in myeloid cells [12]. For example, LXA4 down-regulates IL-1 in a human 
astrocytoma cell line [68] and in BV2 cells, a mouse microglia cell line [69]. LXA4 also reduces 
IL-8 in human neutrophils in vitro [70] and MMP-9 in vivo in a mouse model of endometriosis 
[71].  
In the vascular wall, LXs and ATL block vascular endothelial growth factor-stimulated 
angiogenesis [72] and migration of EC [73]. In addition, LXs stimulate prostacyclin [74] and 
nitric oxide (NO) [75] production in EC, thus promoting SMCs relaxation and subsequently, 
arterial dilation. Since NO also has an impact on inflammation [76], LXA4 could play an indirect 
role by NO modulation. In SMCs, ATL inhibits SMCs proliferation after platelet derived growth 
factor (PDGF) stimulation [77], but otherwise previous studies of LX-induced effects in SMCs 
are scarce. Finally, it has been reported that circulating LXA4 levels are reduced in patients with 
peripheral arterial disease [77], suggesting that this disease may be associated with a failure in the 
resolution of inflammation. 
1.4 FPR2/ALX receptor 
 
The formyl peptide receptor (FPR), subtype FPR2/ALX, was first described as a 
chemotaxis receptor. This seven trans-membrane (TM) G-protein coupled receptor exhibits 86% 
homology to the FPR1 receptor [12] and responds to bacterial peptides initiated with an N-
formylmethionine [78]. Furthermore, other ligands have been described to bind FPR2/ALX, such 
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as different endogenous proteins and lipids [12]. Proteins such as LL-37, serum amyloid A 
(SAA) and formyl peptides are known to transduce pro-inflammatory responses through 
FPR2/ALX [78]. However, other proteins such as annexin A1 [79] or the lipid mediators, LXA4 
[80] and RvD1 [81] were described as FPR2/ALX ligands that exert anti-inflammatory effects on 
neutrophils and monocytes [12].  Furthermore, the binding sites may be different based on the 
ligand’s properties. For example, whereas the sixth TM and the third external loop are crucial for 
peptide/protein binding, the seventh TM with adjacent regions and glycosylation are essential for 
LXA4 binding [82]. This duality of the receptor has been examined in different disease models 
[83], and recently reviewed [84]. Figure 3 depicts some of the effects mediated by FPR2/ALX 
depending on the ligand. Binding assay experiments have confirmed that the highest endogenous 
FPR2/ALX affinity ligand is LXA4 [85]. 
Currently there are FPR2/ALX antagonists on the market that work in vivo, but reports 
claims that they might not be so specific and may also bind FPR1 and FPR3 [78, 86]. The 
generation of knock-out mice lacking the mouse homologue of FPR2/ALX, Fpr2 has allowed the 
examination of the role that this receptor may play in different pathophysiological contexts. So 
far, studies using the knock-out of the mouse homologue of the human FPR2/ALX receptor have 
generated variable results depending on the disease model assessed. For example, Fpr2 knock-out 
mice exhibit exacerbated leukocyte recruitment after mesentery ischemia-reperfusion, paw 
edema and arthritis [87]. However, in a mouse model of asthma, with OVA/alum-induced 
allergic airway inflammation, the lack of the receptor conferred protection to the mice [88]. 
Additionally, in a bowel disease model, mice expressing Fpr2 presented higher inflammatory 
state with more intestinal crypt formation, but protecting the mice from death at later stages [89]. 
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Figure 3: The duality of the FPR2/ALX receptor.  
Based on what ligand binds to the receptor, differential effects will be transduced. For example, ligation of SAA will 
induce a pro-inflammatory response, whereas LXA4 ligation will induce anti-inflammation and pro-resolution. The 
figure depicts the different pro-inflammatory actions triggered by SAA (left) and pro-resolving events triggered by 
LXA4 (right). 
 
Currently there is no knowledge about the use of LXA4 and its analogs in atherosclerosis, 
but evidence supports the possible use of this lipid mediator in CVD. For instance, a genetic 
variation (polymorphism) at the promoter region of FPR2/ALX conferred a low expression of the 
receptor in neutrophils, and this was associated with higher risk of premature myocardial 
infarction [90]. On the other hand, another study exploring polymorphisms of FPR2/ALX 
receptor and coronary artery disease failed to show any association [91].   
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2 Aims 
 
In general, the aim was to unravel the role of FPR2/ALX receptor signaling and its main ligand 
LXA4 in the context of vascular wall pathologies such as atherosclerosis and stenosis. 
 
 Uncover the presence of the receptor FPR2/ALX, in human atherosclerotic lesions and its 
expression in most common cells: macrophages, smooth muscle cells and endothelial 
cells. 
 Explore the Fpr2 signaling in mouse models of atherosclerosis in vivo along with its 
major cells: macrophages, smooth muscle cells and endothelial cells in vitro. 
 Assess a possible therapeutic potential of LXA4 in atherosclerosis and stenosis. 
 Elucidate if the pro-resolution effect of LXA4 is mediated by the FPR2/ALX receptor. 
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3 Material and methods 
3.1 Materials 
All reagents were from Sigma-Aldrich unless otherwise specfied. 
3.2 Experiments performed in the laboratory 
3.2.1 Plasma measurements 
Plasma cholesterol and triglyceride levels were determined by enzymatic assays (Randox 
Laboratories). ELISA was used to evaluate the plasma levels of SAA (Invitrogen) and LXA4 
(Neogen). 
3.2.2 Animal genotyping 
DNA was isolated from ear punches or tail biopsies using E.Z.N.A. kit (OMEGA 
Biotek). All animal experiments were approved by Karolinska ethical committee (#139-12).  
The genotype for Fpr2, ApoE and Ldlr genes was assessed as follows: 
3.2.2.1 Fpr2-/- 
Primers: F1 – tgagtgtcatgtcagaaggagcc, B11 – cggaatccagctacccaaatc and GB4 – 
ataaccttcgggcatggcactc. PCR conditions: 92˚C for 3 min followed by 35 cycles of 92˚C for 30s, 
54˚C for 15 s, and 72˚C for 15 s. A final step of 72˚C for 10 min assured the complete elongation 
of the amplicons. A 2 % agarose gel revealed a 233-base pairs band for the wild-type animals or 
a 351-base pairs band for the knock-out animals. 
3.2.2.2 ApoE-/- 
Primers: oIMR0180 (common forward) – gcctagccgagggagagccg, oIMR0181 (Wild-
type reverse) – tgtgacttgggagctctgcagc and oIMR0182 (Mutant reverse) – gccgccccgactgcatct. 
PCR conditions: 94˚C for 3 min followed by 35 cycles of 94˚C for 30 s, 68˚C for 40 s and 72˚C 
for 1 min. A final step of 72˚C for 10 min assured the complete elongation of the amplicons. A 2 
% agarose gel revealed a 155-base pairs band for the wild-type animals or a 245-base pairs band 
for the knock-out animals. 
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3.2.2.3 Ldlr-/- 
Primers: Ldlr common forward – aggtgagatgacaggagatc, Ldlr wild-type reverse – 
accccaagacgtgctcccaggatga, Ldlr mutant reverse – cgcagtgctcctcatctgacttgt. PCR conditions:  
94o C for 3 min followed by 35 cycles of 94˚C for 30 s, 68˚C for 40 s and 72˚C for 1 min. A final 
step of 72˚C for 10 min assured the complete elongation of the amplicons. A 2 % agarose gel 
revealed a 400-base pairs band for the wild-type animals or a 800-base pairs band for the knock-
out animals. 
3.2.3 RNA isolation 
Multiple murine tissues homogenized in QIAZOL (Qiagen) or cultured cells lysed in 
RLT buffer (Qiagen) were used for the semi-automatic isolation of total RNA (Qiacube; Qiagen). 
RNA concentration was spectrophotometrically measured (Nanodrop 1000; Thermo Fisher 
Scientific) and its quality determined by capillary electrophoresis (Bioanalyzer; Agilent). 
3.2.4 Real-Time PCR 
Reverse-transcription reaction was developed by either Superscript-II kit using random 
hexamers (Life Technologies) or High Capacity RNA to cDNA kit (Life Technologies). Real-
time PCR was developed on a 7900HT Real-Time PCR system (Life Technologies) using 
TaqMan assays (Life Technologies). Results were expressed as 2-ΔCT using hypoxanthine 
phosphoribosyl-transferase (HPRT) or peptidylprolyl isomerase A (PPIA) as housekeeping 
genes, for mouse and human samples respectively. Changes in gene expression due to a treatment 
or genotype were assessed by comparison with the expression of the experimental controls. 
3.2.5 Cell isolation 
Human cells were purified from buffy coats or venous blood. Murine cells were isolated 
after euthanizing the animals by CO2 inhalation.  
3.2.5.1 Human CD4+ positive cells 
Peripheral blood monocyte cells (PBMC) were isolated from buffy coats or peripheral 
blood by means of gradient centrifugation. CD4-antibody-coated magnetic beads (Miltenyi 
Biotec) beads were incubated with the PBMC. The mixture was subsequently exposed to a 
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magnetic field that separated the CD4+ cells from the rest of the cells. The CD4+ cells were either 
incubated with RPMI media supplemented with 10% FCS for 3 days (non-activated CD4+ cells) 
or cultured in CD3/CD28-immobilized-antibodies petri dishes for 3 days (activated CD4+ cells). 
After this period, non-activated and activated CD4+ cells and their supernatants were used to 
stimulate macrophages. 
3.2.5.2 Human Monocytes/Macrophages 
The negative cellular fraction from the CD4+ selection derived from PBMC (mainly 
monocytes) was seeded on a petri dish for 3 h. Non-adherent cells were washed away and the 
attached cells were left to differentiate with 5% FCS and 5% serum obtained from the same 
donor for 3 days. The differentiated cells (macrophages) were exposed for 24h to the CD4+ cells 
and supernatants described in the previous section. 
3.2.5.3 Mouse Peritoneal Macrophages 
Peritoneal cells were isolated from non-stimulated peritoneum of 8-10 weeks old mice 
with 8 ml of RPMI supplemented with antibiotics and 10% FCS. Peritoneal cells were seeded at 
1x106 cells/ml density in petri dishes. After 2-3 h, non-adherent cells were removed. The attached 
cells, F4/80+ by FACS analysis (peritoneal macrophages), were used for further experimentation. 
3.2.5.4 Mouse bone marrow cells 
Mice lower limbs were separated from the body and kept in RPMI supplemented with 
antibiotics and 10% FCS. In a sterile environment, muscles and tendons were removed from 
femurs and tibias. After the removal of the epiphyses, the bone marrow (BM) was isolated from 
the bones using a 21 G needle and cell culture medium. Ammonium-Chloride-Potassium (ACK) 
buffer was used to lyse the erythrocytes. Finally, BM cells were washed, re-suspended in cell 
culture medium and counted. 
3.2.5.5 Mouse smooth muscle cells 
Mouse aortic smooth muscle cells (mSMC) were isolated from 4-6 weeks old mice. The 
aortas were dissected from adjacent tissues, cut into pieces and digested for 4 h with type I 
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collagenase in DMEM with 2 % FCS. FACS analyses determined that more than 90% of the 
cells were positive for -actin. mSMC at passages 1-3 were used in the experiments. 
3.2.5.6 Mouse endothelial cells 
Murine aortic EC (mAEC) were collected from 4-6 weeks old animals. The aortas were 
cut into pieces and digested with type II collagenase for 45 min. After this period, the mixture of 
cells was incubated with magnetic beads (Invitrogen) previously coated with CD31 antibody (BD 
Bioscience). The CD31+ cells were purified by magnetic field separation and cultured in gelatin-
treated microplates in the presence of EC medium (F12\Glutamax DMEM medium 
supplemented with endothelial cell growth factors and heparin). FACS analyses determined that 
the cells exhibited an average of 92% and 94% of purity for CD31 and CD105, respectively. 
mAEC at passages 1-3 were used in the experiments. 
3.2.6 Intracellular calcium measurements 
Free cytoplasmic calcium was measured using a Zeiss Axio system (Zeiss). Freshly 
isolated peritoneal macrophages were exposed to the calcium indicator Fluo-4 (Molecular 
Probes) in Krebs solution (KS). The fluorescence emitted by Fluo-4 (480 nm) was recorded 
every 2 sec for 5-15 min. Single-cell changes in fluorescence were expressed in arbitrary units 
(A.U.). Peritoneal cells exhibiting a characteristic oscillating pattern of variations in intracellular 
calcium were analyzed. The average of the 10 highest values (peaks) and the average of the 10 
lowest values (bases) were collected and the amplitude of the oscillation was calculated as the 
difference between peaks minus bases. The frequencies of oscillation were analyzed by Spectral 
Analysis software (Version 3.0; http://www.molneuro.mbb.ki.se/uhlen/downloadable. php). At 
least 15 cells per field were analyzed from each experiment. 
3.2.7 Flow cytometry 
The cells were fixed in 1% PFA before being used for one of the following protocols. For 
extracellular staining, the cells were incubated with anti-FPR2/ALX antibody (rabbit anti-human, 
Abcam - ab63022) followed by incubation with anti-rabbit dylight-488. For intracellular staining, 
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the cells were permeabilized with Cytofix/Cytoper solution (BD Bioscience), washed twice with 
Perm/Wash buffer (BD Bioscience) and incubated with anti-FPR2/ALX diluted in Perm/Wash 
buffer, followed by incubation with anti-rabbit dylight-488 in Perm/Wash buffer. Unstained cells, 
isotype control and secondary antibody in the absence of the primary were used as negative 
controls to confirm the specificity of the procedure. Median Intensity fluorescence (MIF) was 
recorded and analyzed in 3 independent experiments. 
3.2.8 In vitro efferocytosis assay.  
Efferocytosis assay was performed with pHrodo-marked splenocytes as previously 
described [92]. Briefly, spleens from Fpr2+/+ and Fpr2-/- mice were collected, minced and 
exposed to a UV light source for 8 min to induce apoptosis. Cell apoptosis was confirmed using 
Annexin V and propidium iodide (PI) staining by FACS. The cells were then incubated with 
pHrodo for 30 min. Peritoneal macrophages were incubated with the apoptotic fluorescently-
labeled splenocytes at 1:2 ratio (efferocyte:apoptotic cell). After 4 h of incubation, the non-
uptaken cells were washed and the efferocytes were detached from the plate and subsequently 
analyzed by FACS. MIF of each sample was normalized to the uptake of Fpr2+/+ apoptotic 
splenocyte by Fpr2+/+ macrophages. 
3.2.9 Cell proliferation assay 
mSMC and mAEC proliferation rate was evaluated using WST-1 reagent (Chemicon) as 
previously described [47]. In brief, 3500 cells/well were seeded with DMEM supplemented with 
10% FCS. After 48h, 200 L of phenol red-free DMEM supplemented with FCS and 10 L of 
WST-1 reagent was added to each well. After 2h of incubation, the absorbance of the formazan 
dye formed was measured at 440 nm using a microplate reader (Perkin Elmer).  
3.2.10 Cell migration assay 
The in vitro migration of mSMC was assessed through wound migration assay as 
previously described [67]. Using a sterile 1.15 mm diameter pipette tip, a scratch was created at 
the center of confluent Fpr2+/+ and Fpr2-/- mSMC cultured in 12-wells plates. Multiple regions of 
the scratch were photographed every hour using the Cell-IQ system (Cenibra) for 48 h. The 
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percentage of wound closure over time was determined by analyzing sequential images of the 
same region.  
3.2.11 Immunohistochemistry 
Human atherosclerotic plaques and multiple mouse tissues were used for immunological 
detection of proteins. Cryosections were obtained from tissues previously embedded in Optimal 
Cutting Temperature (OCT) reagent and preserved at -80°C. Alternatively, zinc-formaldehyde 
fixed samples were embedded in paraffin and cut in a microtome. Sections were processed for 
light microscopy or immunofluorescence depending on the antigen of interest and the 
specifications of the antibody. Removal of paraffin and antigen retrieval were specific steps for 
the preparation of the paraffin samples. After those steps, all the sections followed a standard 
immunohistochemistry protocol.  
3.2.11.1 Visible light microscopy 
Human atherosclerotic plaques were stained with the following primary antibodies: 
FPR2/ALX (Abcam, ab63022), CD68 (BD, #556059), CD163 (Novocastra, NCL-CD163), 
CD31 (Dako, JC70A) and -actin (Abcam, ab8211). On the other hand, murine tissues and cells 
were stained with: CD68 (Serotec, MCA1957), CD3 (Abcam, ab19639) and CD4 (Pharmingen, 
553647). Secondary biotinylated antibodies (Vector Labs), Avidin-biotin complex (Vector, UK) 
and NovaRed (Vector, UK) were used for the visualization of the immune recognition; 
counterstaining was done with hematoxylin.  
3.2.11.2 Fluorescence 
The same primary antibodies described in the previous section were used for 
immunofluorescence.  In this context, secondary antibodies were conjugated with Dylight-488 or 
-594 and 4',6-diamidino-2-phenylindole (DAPI) was used to stain the nuclei. Isotype IgG was 
used as negative control. 
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3.2.11.3 Collagen quantification 
Collagen fibers were visualized by means of picrosirius red (Histolab) staining in a 
circularly polarized light microscope (Leica). The staining were performed on eight formalin-
fixed sections collected every 100 µm from the aortic valve cusps. 
3.2.12 Organ bath experiments 
Aortas were quickly dissected, cut into 2-mm long rings and mounted in a Multi Wire 
Myograph System (DMT). In some preparations, the endothelium was removed and compared 
with intact rings. Aortic isometric force development in the presence of several concentrations of 
vasoactive substances was evaluated as previously described [93].  
3.2.13 Biobank 
Karolinska carotid endarterectomy biobank (BiKE) was used to determine the expression 
pattern of FPR2/ALX in human atherosclerosis. Gene expression microarrays hybridized with 
mRNA isolated from 127 atherosclerotic plaques, 10 control arteries, and from circulating 
PBMCs obtained from patients undergoing an endarterectomy procedure were used to measure 
FPR2/ALX expression and to determine its association with several cell markers in a multi-
perspective transcriptomical approach. Additional plaques were used for immunological staining 
of FPR2/ALX and co-localization experiments. Ethical permits were approved by Karolinska 
ethical committee (#02-146 and #02-147).  
3.3 Experiments performed in the animal facility 
3.3.1 Mouse colonies 
3.3.1.1 Fpr2-/- mice 
Fpr2 deficient mice were generated as previously described [86], and genotyped 
according to established protocols described previously in this thesis. Of note, these knock-out 
mice were generated through the insertion of a gene cassette containing a GFP reporter in reverse 
orientation into intron 1 of Fpr2 gene, which prevented transcriptional read-through of the Fpr2 
as well as Fpr3 genes [86]. Therefore, these mice have also been termed Fpr2/Fpr3 knock-out 
mice [94], but will be referred to as Fpr2-/- in the present thesis. 
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3.3.2 Double knock-out mice 
For the purpose of studying the absence of Fpr2 in atherosclerosis, two mice models were 
created. 
3.3.2.1 Ldlr-/- x Fpr2-/- mice 
After backcrossing for at least 8 generations onto C57BL/6J background, Fpr2-/- mice 
were crossed with Ldlr-/- mice (Jackson Laboratory) to generate the Ldlr-/- x Fpr2-/- strain. Age-
matched Ldlr-/- x Fpr2+/+ littermates were used as controls. 12-weeks old males were fed on a 
HFD (Lantmännen, R638) for 8, 12, 16 and 20 weeks.  
3.3.2.2 ApoE-/- x Fpr2-/- mice 
After backcrossing for at least 8 generations onto C57BL/6J background, Fpr2-/- mice 
were crossed with ApoE-/- mice (Taconic) to generate the ApoE-/- x Fpr2-/- strain. Age-matched 
ApoE-/- x Fpr2+/+ littermates was used as controls. ApoE-/- x Fpr2-/- mice were not exposed to 
HFD since these animals develop spontaneous atherosclerosis. 
3.3.2.3 Evaluation of atherosclerosis 
After euthanasia by CO2, aortas were dissected from the surrounding tissues. Thoracic 
aortas were longitudinally opened, pinned, and stained with Sudan IV. The images of the aortas 
were captured using a Leica camera and the analyses were performed using Image J (NIH) in a 
blinded fashion. The area covered by the atherosclerotic lesions divided by the area of the entire 
aorta was calculated and compared by either genotype or treatment. Abdominal aortas were used 
for mRNA extraction. 
 The upper portion of the heart (containing the aortic root) was embedded in OCT and 
frozen at -80°C. 10-m cryosections were collected covering the entire aortic valve, as 
previously described [95]. Serial sections were stained with Oil red-O and lesion area was 
determined in a blinded fashion by image analyses using Leica Qwin. The lesion area and % of 
lesion per cross-sectional vessel area were calculated. Immunohistochemical analysis of CD68, 
CD3 and CD4 was performed at the level of the largest lesion size for each sample. 
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3.3.3 Bone marrow transplantation 
Fpr2-/- mice on a mixed 129SvEv background were used for cell isolation and BMT. 
After euthanasia by CO2, BM cells were collected from the femurs and tibias of either Ldlr
+/+ x 
Fpr2+/+ or Ldlr+/+ x Fpr2-/- donor mice. Recipient Ldlr-/- mice at the age of 8-10 weeks were 
lethally irradiated (800 Rad), and subsequently injected with 5x106 BM cells through tail vein. 
Animals were kept in intra-ventilated cages and antibiotics (sulfadiazine and trimethoprim) were 
administered for 3 weeks. Four weeks after BMT, mice were placed on HFD for 20 weeks. After 
this period, mice were sacrificed and organs were collected for the protocols described below. 
3.3.4 Carotid ligation 
Fpr2-/- and Fpr2+/+ littermates in a mixed background (6–8 weeks old) were subjected to 
total common carotid artery ligation, as previously described [96]. Briefly, after anesthesia 
(Sevoflorane and buprenorphine), a midline incision was performed on the frontal neck from the 
manubrium until 1 cm near the chin. The left common carotid was identified and a 9-0 nylon 
suture was applied just above the carotid bifurcation. Arterial occlusion was confirmed by the 
visual lack of flow in the external and internal carotids. Wound was closed using 6-0 continuous 
suture (Vykril®). An osmotic pump containing either vehicle (15% ethanol) or ATL (10 g/kg) 
was placed in the mouse back. Mice were kept in heat pads until they were fully awaked; then, 
they were transferred back to their cages. Buprenorphine was applied every 12 h for the next 3 
days and no sign of stroke was observed in any mice. The animals were sacrificed 4 weeks after 
the implantation of the pump. Perfusion fixation was performed immediately after CO2 
euthanasia. Heart puncture was performed with a 25 G needle for the infusion of 4% zinc-
formaldehyde in PBS under physiologic pressure. Blood was drained through an incision of the 
inferior vena cava and perfusion was continuous for 10-15 min. The ligated left and the non-
ligated right carotid arteries were excised and post-fixated overnight with 4% PBS-buffered 
formaldehyde; afterwards, the arteries were transferred to 70% ethanol and embedded in paraffin.  
Marcelo Heron Petri  The role of FPR2/ALX in the vascular wall 
24 
 
3.3.4.1 Evaluation of carotid intima 
Paraffin-embedded carotid arteries were cut in series of 8-10 sections (10 m each) every 
100m. The morphology of the arteries was evidenced by means of hematoxilin-eosin staining. 
Using Image J software, the circumference of the external elastic lamina (EEL), the internal 
elastic lamina (IEL), and the luminal border (LB) were measured. Areas were calculated from 
circumference measurements assuming a circular structure under in vivo conditions. Total vessel 
area, luminal area, total wall area, medial area and intimal area were calculated from EEL- and 
LB-circumference, by subtracting LB-area from EEL-area, IEL-area from EEL-area and LB-area 
from IEL-area, respectively.  
3.4 Data analysis 
Clinical parameters are expressed as median and ranges. Univariate correlations between 
continuous variables and FPR2/ALX mRNA levels were performed using Spearman correlation, 
and binary values were compared using Fisher’s exact test. Mann-Whitney U test or Student t-
test was used for comparisons between 2 groups depending on the population distribution. One-
way or two-way analysis of variances (ANOVA) as appropriate, with Kruskall-Wallis or 
Bonferroni post-hoc test respectively, were used for multiple comparisons. P<0.05 was 
considered as significant. All analyses were performed using SigmaPlot version 12.5 (Systat 
Software Inc). Experimental data are expressed as mean ± standard error of the mean (SEM). 
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4 Results  
4.1 FPR2/ALX expression in human atherosclerotic lesions  
In Paper I, immunohistological examination of human atherosclerotic plaques revealed 
three major cell types expressing FPR2/ALX, namely macrophages, SMC and EC. Furthermore, 
mRNA levels of FPR2/ALX in human atherosclerotic plaques were significantly higher 
compared with healthy arteries, and were significantly correlated with mRNA levels of markers 
for monocytes (CD14) and macrophages (CD163) but not with mRNA levels of a neutrophil 
marker (CD66b). Subsequently, the clinical characteristics of the patients donating the vascular 
samples were added into a multivariate regression model in an attempt to establish the 
association of FPR2/ALX mRNA levels with clinical features of disease. This analysis revealed 
that FPR2/ALX mRNA levels in atherosclerotic plaques were significantly associated with age 
and creatinine and exhibited an inverse correlation with recent clinical manifestations, stratified 
according to none (0), past (>3 months; 1), or recent (<3 months; 2) clinical signs of cerebral 
ischemia (Paper I). Since the patients with either none or longer time to clinical signs of stroke 
also exhibited the highest FPR2/ALX mRNA levels, the interpretation of these data was that 
FPR2/ALX expression was highest in the most stable atherosclerotic lesions.  
4.1.1 Macrophages 
The co-localization of FPR2/ALX with a macrophage marker by immunohistochemistry 
suggests that the receptor is active in this myeloid cell. This was further supported by the 
significant correlation between the mRNA levels for FPR2/ALX and macrophage markers, 
besides, these findings were accompanied by a significant correlation of FPR/ALX mRNA with 
cytokines such as IL-1, CXCL-1 and IL-6 (Paper I). Furthermore, in a subset of patients, 
peripheral blood mononuclear cells (PBMC) were also isolated and in line with the findings in 
plaques, the analysis of mRNA levels in circulating PBMCs revealed a similar significant 
positive association between FPR2/ALX and IL-1 and CXCL-1 but not for IL-6 (Paper I).  
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Since these findings indicated a pro-inflammatory action of monocyte/macrophage 
FPR2/ALX expression in the context of atherosclerosis, human cells were subsequently studied 
in vitro (Paper III). These experiments revealed that pro-inflammatory stimuli, i.e T-
lymphocytes, their supernatants, IFN-, and LPS induced FPR2/ALX up-regulation in human 
macrophages and THP-1 cells. However, THP-1 cells exposed to LXA4 (100 nM) for 24 h 
exhibited significantly reduced mRNA levels of MMP-9, IL-1 IL-8, and CXCL-1 (Paper I). 
Taken together, in humans, FPR2/ALX is highly expressed in the atherosclerotic plaque, 
mainly on monocytes/macrophages. The receptor is up-regulated by activated CD4+ cells and 
there is a positive correlation of mRNA of FPR2/ALX receptor with cytokines production more 
importantly in plaque then in circulating cells. These findings suggest that FPR2/ALX is 
associated with inflammation in the atherosclerosis context. 
4.2 Mouse Fpr2 in the context atherosclerosis  
With the information that human plaques are rich in FPR2/ALX and that it might impact 
plaque stability, three different murine models of atherosclerosis were used in order to determine 
the role of this receptor in the disease. 
First, mice lacking both Fpr2 and Ldlr were generated, and evaluated for the diet-induced 
atherosclerosis at different time points (Paper I). Interestingly, these experiments revealed a time-
dependent effect, in which Ldlr-/- x Fpr2-/- mice exhibited a delayed atherosclerosis development 
compared with Ldlr-/- x Fpr2+/+. The results showed that after 12 weeks on HFD, mice lacking the 
receptor exhibited significantly smaller lesions compared with Fpr2 expressing mice (Figure 4). 
Second, to specifically examine the role of myeloid cell Fpr2 in atherosclerosis, BMT was 
performed. These experiments pointed to pro-atherogenic signaling through myeloid Fpr2, since 
Ldlr-/- mice receiving Fpr2-/- BM exhibited a reduced atherosclerosis compared with those 
receiving Fpr2+/+ BM (Figure 4). 
The third and final mouse model of atherosclerosis generated was ApoE-/-. Being either 
wild-type or knock-out for Fpr2 (Figure 4). These mice develop spontaneous atherosclerosis on 
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normal chow diet. Importantly, the findings in ApoE-/- mice corroborated those observed in HFD-
fed Ldlr-/- mice, since mice lacking Fpr2 on chow diet exhibited significantly smaller 
atherosclerotic lesions compared with Fpr2 expressing mice (Figure 4).  
Interestingly, when the latter ApoE-/- and Fpr2 double knock-out mice were exposed to 
ATL treatment by osmotic mini-pumps atherosclerotic lesion size was reduced, whereas in 
ApoE-/- mice lacking Fpr2, ATL treatment did not induce any significant effects. ATL treatment 
significantly decreased the amount of CD68 positive cells in the lesions and significantly reduced 
IL-6 and MMP-13 mRNA levels (Paper V). The latter effect was not only observed locally in the 
aorta, but also in other organs such as spleen and lung, indicating systemic anti-inflammatory 
effects of ATL treatment. Interestingly, no ATL-induced effects were observed in ApoE-/- x Fpr2-
/- mice and ATL-treatment was not associated with changes in circulating leukocytes. 
Given that the consistent findings of reduced atherosclerosis induced by Fpr2 deletion in all 
three models explored were in contrast to the anti-inflammatory effects of LXA4 in vitro (Paper 
III) and the anti-atherosclerotic effects of ATL in vivo (Paper V), the concentration of putative 
Fpr2 agonists was also explored. These results showed that the circulating levels of the pro-
inflammatory agonist SAA were 296 + 62 g/mL, whereas LXA4 levels were 34 + 3.3 ng/mL. 
This represent a difference around 10 000 fold difference favoring the pro-inflammatory ligand 
(Paper I). 
Importantly, serum lipid levels and leukocyte counts were not altered by Fpr2 deletion in 
any of the mouse models explored (Paper I, Paper V).   
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Figure 4: Atherosclerotic lesion evaluated in multiple Fpr2 deficient animal models. 
Atherosclerosis lesions measured in aortic root and en face respectively in Ldlr-/- x Fpr2-/- (A and B), Ldlr-/- 
transplanted with either Fpr2+/+ or Fpr2-/- BM (C and D) and ApoE-/- x Fpr2-/- (E and F). 
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4.2.1 Leukocytes 
Given that macrophages were associated with FPR2/ALX expression in human 
atherosclerotic lesions (Paper 1), the effects of murine Fpr2 deletion was subsequently explored 
in vitro using resident peritoneal macrophages. Macrophages derived from Fpr2-/- mice exhibited 
less calcium oscillations compared with those derived from wild-type mice (Paper I). These 
macrophages also exhibited a lower efferocytosis activity when exposed to apoptotic cells (Paper 
I), suggesting a reduced activation of Fpr2-/- macrophages. This phenotype was accompanied by 
significantly lower mRNA levels of IL-6 and IL-1 (Paper I). These observations corroborated 
the results in human atherosclerotic plaques, which exhibited a significant positive correlation 
with these cytokines and FPR2/ALX expression (Paper I). 
Since atherosclerosis progression is related with the ingress of leukocytes to the lesions, 
the macrophage marker CD68 was quantified in the aortic root of the studied animals. These 
experiments revealed a significantly decreased macrophage content in Ldlr-/- x Fpr2-/- mice and in 
Ldlr-/- mice transplanted with Fpr2-/- BM (Figure 5 A).  
Interestingly, ApoE-/- mice receiving ATL treatment exhibited significantly smaller 
lesions and a reduction of CD68 expression in the aortic root (Figure 5 C), supporting the anti-
inflammatory properties of ATL through of Fpr2 signaling. 
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Figure 5: Macrophage presence in several Fpr2-defcient atherosclerotic models 
CD68 expression in aortic roots of (A) Ldlr-/- x Fpr2-/-, (B) Ldlr-/- with BM Fpr2-/- and (C) ApoE-/- x Fpr2-/- mice. 
 
4.2.2 SMC 
In addition to macrophages, cells expressing the SMC marker -actin also exhibited 
positivity for FPR2/ALX in human atherosclerotic lesions (Paper I). Therefore, Fpr2 signaling in 
aortic mSMC derived from Fpr2+/+ and Fpr2-/- mice was further explored. Fpr2 expression in 
SMC was determined by immunofluorescence, as shown in the cover image (Fpr2 in red, -actin 
in green and DAPI in blue, Paper I). Interestingly, mSMC derived from Fpr2-/- mice exhibited a 
specific phenotype as compared to Fpr2+/+ mSMC. First, mRNA levels of several components 
involved in collagen deposition and maturation were significantly lower in Fpr2-/- compared with 
wild-type mSMC (Paper I), whereas ECM degrading pathways appeared activated by means of 
increased MMP-13 and reduced Timp1 mRNA levels in Fpr2-/- mSMC (Paper I). The latter 
findings were supported by significantly less collagen in the atherosclerotic lesions of Ldlr-/- x 
Fpr2-/- compared with Ldlr-/- x Fpr2+/+ mice. Interestingly, the latter finding was not observed 
Marcelo Heron Petri  The role of FPR2/ALX in the vascular wall 
31 
 
after BMT, supporting that structural cells, such as mSMC, and not myeloid cells mediated those 
changes in lesion collagen (Figure 6). 
 
 
 
Figure 6: Total collagen of aortic root comparing Fpr2-deficient and expressing vascular wall. 
The picture represents the total amount of collagen giving by picrosirius red staining under polarized light of (A) 
Ldlr-/- x Fpr2-/- and (B) Ldlr-/- transplanted with either Fpr2-/- or Fpr2+/+ BM. 
 
In addition to the differences in collagen, Fpr2-/- mSMC also exhibited a 
significantly increased proliferation compared with wild type mSMC (Figure 7 A). In a wound 
migration assay Fpr2-/- mSMC in addition exhibited increased migratory properties compared 
with wild type mSMC (Paper II). Using the latter assay, ATL treatment significantly reduced 
migration of Fpr2+/+ SMC, whereas Fpr2-/- mSMC migration was unaltered after ATL treatment 
(Paper 2).  
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Figure 7: Proliferation rate of Fpr2-deficient cells from components of the vascular wall  
Proliferation rate in absorbance (OD) of (A) mouse aortic smooth muscle cells (mSMC) and (B) mouse aortic 
endothelial cells (mAEC).  
 
Given these marked phenotypic changes of Fpr2 deletion in terms of mSMC 
responses in vitro, the role of Fpr2 signaling in mSMC proliferation and migration was 
subsequently examined in vivo. Using the total carotid ligation model, a significant reduction of 
intimal hyperplasia after ATL treatment was revealed (Figure 8 B). Since the latter effects of 
ATL were observed only in wild type mice, and not in Fpr2-/- mice, these experiments further 
reinforced the importance of ATL signaling by means of Fpr2 in the SMC response to vascular 
injury.  
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Figure 8: ATL effects on atherosclerosis and intima formation after caroti ligation 
Atherosclerosis lesions of ApoE-/- x Fpr2+/+ and ApoE-/- x Fpr2-/- treated either with vehicle (15% ethanol) or aspirin-
triggered lipoxin (ATL) at aortic root (A) and en face (B). Intima formation of Fpr2+/+ (C) and Fpr2-/- (D) treated with 
either vehicle or ATL after total carotid ligation. On the right side representative figures are shown. 
 
4.2.3 Endothelial cells 
The third cell type, which was identified as expressing Fpr2 in human atherosclerotic 
lesions, was the EC (Paper I). These observations prompted for the exploration of Fpr2 signaling 
in EC function and activation. To this end, aortic ECs were isolated from mice wild type and 
Fpr2-/- mice and examined in vitro. First, Fpr2-/- mAEC proliferated significantly slower 
compared with Fpr2+/+ mAEC (Figure 8 B). Second, mRNA levels of the adhesion molecules 
VCAM-1 and ICAM-1 were significantly higher in Fpr2-/- mAEC compared with Fpr2+/+, 
whereas NOS-3 mRNA levels were significantly lower (Paper IV). Since the latter enzyme is of 
importance for vascular relaxation, the notion that Fpr2 signaling confers better endothelial 
function was explored in organ bath experiments.  
Endothelium-intact murine aortic rings derived from Fpr2-/- mice exhibited significantly 
decreased acetylcholine-induced relaxations compared with those derived from Fpr2+/+ mice 
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(Paper IV). In contrast, no significant difference between the genotypes was observed when the 
endothelium were removed from the aortic rings 
To finally assess the role of EC Fpr2 signaling in vivo, physiological angiogenesis was 
explored in neonatal hearts. In histological analysis, hearts derived from Fpr2-/- mice exhibited 
significantly lower vessel counts positive for -actin (Paper IV) compared with Fpr2+/+ mice, 
which corroborates the in vitro finding on decreased proliferation in Fpr2-/- mAECs (Figure 7 B). 
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5 Discussion 
The results of the present thesis identified three important target cells for LX in 
atherosclerosis, based on the co-localization of FPR2/ALX with macrophages, SMC and EC in 
human atherosclerotic lesions. The signaling though this receptor in each of these cell types was 
in addition explored and revealed to be complex, with both pro- and anti-inflammatory responses 
being identified. In vivo models of atherosclerosis, intimal hyperplasia and neoangiogenesis 
confirmed the pivotal role of Fpr2 signaling in pathophysiological processes of disease. Finally, 
the results obtained indicate a potential benefit of ATL treatment in CVD. 
5.1 FPR2/ALX in human atherosclerotic lesions 
Morphological studies of human atherosclerotic lesions have previously demonstrated the 
expression of several receptors for lipid mediators on different cells types, such as for example 
the BLT and CysLT receptors for LTs [47, 97], Such studies may be crucial for the possibility of 
identifying potential targets in atherosclerosis to be moved forward from observational patient 
studies to mouse models and the exploration of their pathophysiological role of those receptors’ 
signaling in the atherosclerotic process. Paper I showed that key components of atherosclerosis 
such as macrophages, SMC and EC expressed FPR2/ALX. This is supported by other works 
describing the FPR2/ALX receptor in primary macrophages [98] and fresh isolated neutrophils 
[90], confirming the presence of this receptor in myeloid cells. In terms of vascular structural 
cells, EC, more specifically HUVECs are known to respond to FPR2/ALX ligands [99] and 
express the receptor [72]. Finally, previous to this thesis FPR2/ALX signaling was reported only 
in SMCs isolated from saphenous veins [77] and Paper I was the first report on arterial SMC 
expressing the FPR2/ALX. 
In human atherosclerotic lesions, FPR2/ALX expression was significantly higher 
compared with healthy vessels and exhibited a positive correlation with markers for monocytes 
and macrophages (Paper I). These findings were further supported by the results in Paper III 
showing a significant up-regulation of FPR2/ALX mRNA after pro-inflammatory stimuli. These 
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results suggest that the high level of FPR2/ALX mRNA levels in atherosclerotic lesion compared 
with healthy arteries discovered in Paper I, could be due to leukocyte recruitment and 
monocyte/macrophage presence in the plaque. 
It is known that CD4+ cells are decisive for plaque development in human atherosclerosis 
[100, 101] and in mouse models [102]. Based on the observation that FPR2/ALX was up-
regulated in atherosclerotic lesions (Paper I), which are rich in CD4+ cells, the hypothesis was 
raised that activated CD4+ could promote FPR2/ALX expression in macrophages/monocytes. 
The results of Paper III indicated that activated CD4+ cells released a soluble factor, which 
induced an up-regulation of FPR2/ALX in macrophages/monocytes, with a pronounced response 
at the mRNA level, but to a lesser extent, albeit significant, at the protein level. Previous studies 
have revealed that IFN- up-regulates FPR2/ALX mRNA in microglia from mice [103], in 
human enterocytes [104] and macrophages [105], supporting that a pro-inflammatory milieu 
induces FPR2/ALX up-regulation. 
Whereas LXA4 reduced cyto- and chemokine levels in human monocytes in vitro, the 
mRNA levels of FPR2/ALX in both atherosclerotic lesions derived from patients undergoing 
carotid endarterectomy, and in circulating leukocytes from a subset of these patients, were 
positively associated with cyto- and chemokine mRNA levels (Paper I). These findings support 
the notion that FPR2/ALX signaling may be associated with both pro- and anti-inflammatory 
signaling. Interestingly, LXA4 concentrations decrease with age and in peripheral artery disease 
compared with healthy subjects [77]. These observations support the failure in the resolution of 
inflammation in atherosclerosis and that this possibly could be due to lack of ligand rather than 
lack of the receptor, and that FPR2/ALX is activated by pro-inflammatory ligands in the absence 
of LXA4. Finally, high expression of FPR2/ALX mRNA in human atherosclerotic lesions was 
independently associated with features of more stable plaques in a multivariate analysis (Paper I).  
Taken together, the observational studies of human atherosclerotic lesions and cells in the 
present thesis (Paper I and III) suggest that, although LXA4 induced anti-inflammatory responses 
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in monocytes in vitro, a pro-inflammatory response appeared to dominate and be transduced 
through FPR2/ALX in human atherosclerotic lesions. In contrast, the results suggested that 
FPR2/ALX was associated with a more stable plaque phenotype.  
One important limitation of the above associations using mRNA levels of FPR2/ALX is 
that the receptor mRNA levels may not always reflect its protein levels. This notion was initially 
reported in human macrophages, in which two different promoter regions were identified, which 
control the regulation of FPR2/ALX expression, and that one of the promoters yielded a longer 
mRNA, which did not translate into protein in macrophages [105]. Those findings were further 
extended in Paper III of the present thesis showing that the increase in FPR2/ALX protein levels 
after stimulation of human monocytes were less pronounced compared with what was observed 
for mRNA levels. In addition, an intracellular localization of FPR2/ALX was detected in human 
monocytes (Paper III), which also raises the question whether the intracellular receptor proteins 
are functional. One possibility could be that the intracellular receptor pool either translocates to 
the cell surface upon activation or represents a result of receptor internalization following agonist 
stimulation [106].  Interestingly, similar intracellular localizations have been reported for other 
G-protein coupled receptors, such as CysLT receptor [97] and angiotensin receptor [107], but the 
exact role of the intracellular FPR2/ALX in monocytes remains to be established. Other 
limitations to be considered for this part of the study are that control arteries were not from 
carotids, the cross-sectional design of the cohort making associations of mRNA levels to 
prognosis or outcome of patient not possible, and the stratification of stable/unstable plaques 
based on clinical signs rather than morphological plaque analysis. 
5.2 The role of Fpr2 in murine models of atherosclerosis 
To explore the causal role of FPR2/ALX in atherosclerosis, the effects of genetic deletion 
of the receptor, and the effects of LXA4 was subsequently evaluated in the thesis project. To this 
end, mouse models representing different approaches were generated and used to define the role 
of the murine FPR2/ALX homologue (Fpr2) in the development of atherosclerosis. Genetic 
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deletion of Fpr2 reduced atherosclerosis in both Ldlr-/- mice fed a HFD (Paper I) and in ApoE-/- 
on a chow diet (Paper V). The initial study showed that in the development of atherosclerosis, 
Fpr2 deletion protected against atherosclerosis development in the initial phase of the disease, 
whereas no difference in terms of plaque burden were observed at later stages of disease (Paper 
I). This finding is in agreement with one recent study, published after our original report, that 
Fpr2 expression is reduced in advanced plaque compared with early stages [108]. This could be 
one possible explanation why later stages (after 16 and 20 weeks on HFD) exhibited no 
differences in terms of atherosclerosis (Paper I).  
Since the mice generated are global knock-out, it was important to discriminate if the 
observations were due to structural cells or myeloid cells. A BMT was performed and revealed 
that after 20 weeks on HFD, Fpr2 promoted atherosclerosis in same fashion as in the Ldlr-/- x 
Fpr2-/- mice (Paper I). These finding hence confirmed that leukocytes expressing Fpr2 were 
determinants of plaque development.  
To further extend the studies of the role of Fpr2 in atherosclerosis, another model was used, 
namely ApoE-/- mice with and without Fpr2 deletion. This study again showed that Fpr2 
expressing hyperlipidemic mice presented pro-inflammatory properties with more atherosclerosis 
compared with mice lacking the receptor (Paper V). These results were in line with the 
observations in Ldlr-/- mice (Paper I), but in contrast, another study showed that Fpr2 conferred 
protection at initial stages of the disease [109].  
The protection against atherosclerosis by Fpr2 deletion was not related to changes in serum 
lipids (Paper I and Paper V), and suggests that pro-inflammatory rather than anti-inflammatory 
responses are transduced through Fpr2 in atherosclerosis. Measuring serum levels of two main 
ligands for Fpr2 showed remarkable differences in ligand concentrations, the concentration of 
SAA being around 10,000 fold higher compared with LXA4 (Paper I). These results suggest that 
Fpr2 transduced a pro-inflammatory response since in the atherosclerotic context the pro-
inflammatory ligands are more abundant. Of note, pro-inflammatory FPR2/ALX ligands are 
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associated with atherosclerosis. For example such as LL-37 has been reported in human lesions 
[110, 111] and knock-out of the mouse homologue for LL-37 (mCRAMP) reduces 
atherosclerosis in ApoE-/- mice [112]. Besides, SAA promotes atherosclerosis in vivo [113] and 
foam cell formation in vitro Fpr2 dependently [114, 115].  
The interpretation of our data is hence that during the development of atherosclerosis, Fpr2 
signaling is mandatory and driven by the abundant pro-inflammatory ligands such as SAA. 
However, SAA increases as the disease develops [116], and another study using very young 
ApoE-/- mice on HFD showed that Fpr2 signaling was protective during initial atherosclerosis 
development [109]. The later experimental protocol (early time point and HFD in ApoE-/- mice), 
was not evaluated in the present project. Additionally, it should also be noted that the mouse used 
in the current thesis (Paper I and V), lacks both Fpr2 and Fpr3, whereas those used in the other 
study lacked only Fpr2 [109].  
In summary, extensive studies of Fpr2 in mouse models of atherosclerosis in the current 
thesis suggest that Fpr2 is activated by pro-inflammatory ligands resulting in signaling that 
accelerates atherosclerosis. 
5.2.1 Leukocytes 
As described above, macrophages in human atherosclerotic lesions expressed FPR2/ALX 
(Paper I), monocyte/macrophages up-regulated FPR2/ALX expression after inflammatory 
stimulation, and THP-1 cells exposed to LXA4 reduced their levels of pro-inflammatory 
mediators (Paper III). In mice, Fpr2 signaling was associated with increased atherosclerotic 
plaque formation, which was mimicked by BMT, supporting the role of Fpr2 as a pro-
inflammatory receptor in atherosclerosis.  
The use of cells with genetic deletion of Fpr2 offers several advantages compared with 
other methods for targeting Fpr2 signaling in vitro and in vivo: (1) The use of FPR2/ALX 
antagonists has been widely used in many studies. The results with these compounds must be 
interpreted with care, these antagonists have a high affinity towards FPR2, but t-Boc-FLFLF has 
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been reported to also binds to FPR1 [117, 118] and WRWWWW also binds to FPR3 [119] 
receptors. (2) siRNA might not be very efficient by the fact that the receptor is recycled after 
internalization upon ligand binding [120] and if internalization is inhibited apoptosis mechanisms 
are triggered [106]. (3) Different myeloid cells exhibit different Fpr2 expression, being highly 
expressed in neutrophils [121], to a lesser extent in monocytes and down-regulated as 
differentiation to macrophages occurs [98].  
Since the observation that Fpr2 knock-out mice exhibited less atherosclerosis compared 
to wild-type, which was reproduced by BMT (Paper I) strongly suggested that BM cells could 
impact lesion, and therefore the effects of Fpr2 deletion in leukocytes were further explored.  
Aortic roots of Ldlr and Fpr2 double knock-out mice exhibited a reduced amount of 
CD68-postive cells compared with Ldlr-/- x Fpr2+/+ (Paper I). In addition, the levels of pro-
inflammatory mediators were reduced in Fpr2-/- macrophages and those cells also exhibited lower 
intracellular calcium oscillations compared with wild-type macrophages (Paper I). Taken 
together, these results indicate that Fpr2 may be involved in both leukocyte recruitment and 
activation in the context of atherosclerosis, and further reinforces the major pro-inflammatory 
component of Fpr2 signaling in atherosclerosis. 
5.2.2 SMC 
In addition to leukocytes, immunohistological stainings identified FPR2/ALX expression 
in SMCs of human atherosclerotic lesions and Fpr2 expression in murine aortic SMCs (Paper I). 
Interestingly, Fpr2-/- SMCs exhibited a specific spontaneous phenotype ex vivo, with an increased 
proliferation (Paper II), and mRNA expression patterns indicative of reduced collagen production 
and maturation, and increased collagen break-down (Paper I). The latter notion was supported by 
measuring the total collagen in atherosclerotic lesions in vivo. Aortic root lesions of Ldlr-/- x  
Fpr2-/- contained less collagen compared with lesions in Ldlr-/- x Fpr2+/+ mice (Paper I). 
Importantly, transplantation of Fpr2-/- BM to Ldlr-/- mice did not mimic this response, suggesting 
that vessel wall Fpr2 expression is pivotal for changes in atherosclerotic lesion collagen content.  
Marcelo Heron Petri  The role of FPR2/ALX in the vascular wall 
41 
 
Since decreased collagen content in atherosclerotic lesions is a hallmark of unstable 
plaques [122], these results suggest that although Fpr2 may confer increased atherosclerosis, 
signaling through this receptor appears to induce a more stable plaque phenotype (Paper I). 
Those results are indeed interesting given the observations in human disease; that Fpr2 
expression increased with atherosclerosis and was inversely correlated with clinical signs of 
cerebral ischemia in our biobank study (Paper I). Taken together, the translational interpretation 
of the human observational (Paper I) and murine interventional studies of the present thesis 
(Paper I and V) is hence that Fpr2 signaling may be beneficial in terms of stimulating SMC to 
stabilize atherosclerotic lesions.   
The relationship with inflammation and SMC motility has been explored for other lipid 
mediator receptors such as BLT1. For example, LTB4 increases chemotaxis that is absent in 
BLT1
-/- cells [66], and by BLT1 antagonist, showing less SMC migration after LTB4 challenge 
[47]. Therefore, we subsequently explored if ATL was able to exert its anti-inflammatory effect 
through Fpr2 by reducing SMC migration. Whereas one previous study described that ATL 
inhibited the proliferation of venous SMC in response to PDGF [77], the receptor involved in 
LX-induced responses in SMCs had not been explored. Using a wound assay, it was revealed that 
SMCs lacking Fpr2 exhibited increased migratory properties compared with wild type cells. 
Treatment with ATL significantly reduced SMC migration in wild-type but not in Fpr2 knock-
out SMCs, hence providing the first evidence for ATL signaling by means of Fpr2 in SMCs 
(Paper II). 
To explore the pathophysiological role of Fpr2 signaling in vivo, a carotid ligation model 
of intimal hyperplasia was established in the present thesis project. Despite the obvious SMC 
phenotype in vitro, those in vivo experiments did not reveal any significant differences in terms 
of neo-intima formation associated with genotype (Paper II). The reason for the genotype 
difference observed in vitro was not observed in vivo could be due to the fact that in neo-intima 
formation models, the migration and proliferation of SMC occur mainly at the first 2 weeks [17] 
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and in the present project, mice were sacrificed 4 weeks after carotid ligation. It should also be 
mentioned that compensatory mechanisms for the lack of Fpr2 receptor in this model could not 
be excluded. 
In contrast to the lack of a spontaneous phenotype, wild-type and Fpr2 knock-out mice 
exhibited an important difference in the response to ATL treatment. Whereas ATL reduced 
intimal hyperplasia after carotid ligation in wild-type mice, this Fpr2 ligand was ineffective in 
altering the response to ligation in Fpr2 knock-out mice (Paper II). These observations may have 
therapeutic implications, which will be discussed below, and also provide compelling evidence of 
ATL signaling by means of Fpr2 in the response to vascular injury.  
In summary, the present thesis identified FPR2/ALX expression on SMCs in human 
atherosclerotic lesions, and revealed that a major role of ATL signaling through Fpr2 in SMC 
migration in vitro and intimal hyperplasia formation in vivo. In addition, Fpr2 was associated 
with pathways of increased collagen production and maturation, and decreased collagen break-
down, which may drive the atherosclerotic lesions towards a more stable phenotype as suggested 
from both human observational studies (Paper I) and murine atherosclerosis models (Paper I and 
V).  
5.2.3 Endothelial cells 
EC represented the third FPR2/ALX expressing cell type identified in human 
atherosclerotic lesions in the present thesis (Paper I). In the initiation of the atherosclerotic lesion 
EC recruit leukocytes to the vascular wall and regulate vascular tone. Early phases of 
atherosclerosis are characterized by an endothelial dysfunction, which can be detected as reduced 
endothelium-dependent vascular relaxations both in vivo and in vitro [29, 123, 124]. Organ bath 
experiments revealed that Fpr2 knock-out mice exhibited reduced endothelium-dependent 
relations in response to ACh (Paper IV), suggesting that these mice have an endothelial 
dysfunction. Although previous reports that have shown vasoactive effects of potential 
FPR2/ALX agonists [125, 126], the receptor involved in the responses were not explored in those 
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studies. The implications for these findings in vivo has also been supported by studies in rats, in 
which intra-venous LXA4 causes a reduction of blood pressure in short term (~4 min), while 
blocking the LXA4 production or adding FPR2/ALX antagonists abolished this effect [125]. In 
support of a major role for Fpr2 in regulating endothelial function, Fpr2-/- EC exhibited lower 
levels of mRNA of NOS-3, the endothelial type of nitric oxide synthase (Paper IV).  
Since the focus of this thesis is atherosclerosis, which is an arterial disease, the task to 
isolate aortic EC from mice was taken. It was crucial to isolate EC from mouse aorta based on 
that other sources of EC such as lung or kidney, very rich in capillaries, would have a 
contamination of venous EC. Once primary murine aortic EC cultures were established, two 
experiments were performed; (1) mRNA isolation and (2) evaluation of EC phenotype (Paper 
IV).  
For ECs to be able to recruit leukocytes, the expression of cellular adhesion molecules are 
important. In Paper IV, VCAM-1 and ICAM-1 were increased in Fpr2-/- EC, suggesting that Fpr2 
deletion promoted endothelial activation. These results are hence in sharp contrast to the 
observations of a lower inflammatory state in Fpr2-/- macrophages (Paper I, cf. supra), and 
support that EC Fpr2 signaling would potentially reduce cell recruitment towards the 
inflammation site. Interestingly, previous studies have shown that Fpr2-induced endothelial 
adhesion was dependent on an integrin conformational change on leukocytes, which allowed 
monocyte integrin binding to EC VCAM-1 and ICAM-1 [109]. The higher levels of ICAM-1 and 
VCAM-1 in ECs derived from Fpr2-/- mice compared with those derived from wild-type mice 
(Paper IV) point to differential effects of Fpr2 signaling on monocytes and EC. This suggests that 
the same receptor may promote inflammation by leukocyte recruitment and activation, by means 
of direct effects on monocyte integrins, whereas Fpr2 activation on EC may limit inflammation 
by down-regulation of adhesion molecules. By this way, reduced recruitment of inflammatory 
cells to a site of high Fpr2 agonist concentrations. These results are in agreement with previous 
results with the same mice, in which intra-vital microscopy after 30 min of ischemia showed that 
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Fpr2-/- recruited more cells after reperfusion suggesting higher endothelial activation compared to 
Fpr2+/+ mice [86, 94]. However, further studies are needed to determine the relative role of 
different Fpr2 expression cell types in different inflammatory conditions.  
The enhanced EC activation after genetic targeting of Fpr2 in Paper IV is in line with the 
studies of SMC (Paper I and Paper II), in which Fpr2 signaling reduced SMC migration and 
proliferation in vitro, and conferred protective effects on the development of intimal hyperplasia 
in response to carotid ligation in vivo. Taken together, whereas Fpr2 may mediate both pro- and 
anti-inflammation in leukocytes, Fpr2 signaling may be predominantly anti-inflammatory in 
structural cells of the vascular wall, i.e. SMCs and ECs (Paper II and Paper IV). 
As a subsequent step, EC proliferation was evaluated and showed to be impaired in Fpr2 
knock-out EC. There are however some important methodological considerations to take into 
account: (1) The time from sacrifice until the final yield of the cells (around 6 h) and the 
incubation with collagenases may put EC in the process of de-differentiation and the cells might 
not express the same levels of EC markers as in their original state. (2) EC were studied in 
culture dishes without shear stress, which may alter EC responses [29] and it cannot be excluded 
that Fpr2 expression/signaling could be flow dependent and that important information may be 
missed under static conditions.  
One crucial observation of the present work is the different proliferation profile observed 
by Fpr2 signaling in EC (Paper IV) compared to SMC (Paper II). Differential effects on SMC 
and EC have been described as LTB4 promotes SMC proliferation [47] whereas induces EC 
apoptosis [127] for example. No previous reports have explored specifically the Fpr2 signaling 
on EC proliferation, but LXA4 reduced VEGF-induced EC proliferation and migration [72, 99], 
supporting that LXA4-Fpr2 signaling would modulate EC proliferation.  
Finally it was sought if EC Fpr2 could play a physiological role during angiogenesis. It is 
known that from birth until the 3-4 week, mice gain at least 3-4 times their weight. This will 
demand that EC would proliferate in higher rate, and generate more vessels to compensate such 
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growth [128]. The quantification of vessels in 3 weeks old mice is an established model of 
neoangiogenesis [128, 129], which was established to study the role of Fpr2 signaling in 
angiogenesis. Interestingly, the number of vessels was reduced in Fpr2-/- mice compared with 
Fpr2+/+ mice. These in vivo results confirmed the observation in vitro that EC lacking Fpr2 
exhibited a lower proliferation. This lower amount of neonatal cardiac vessel number did not 
induce any apparent changes in development, since no differences in terms of size or weight of 
the mice were associated with the genotype (Papers I, II and IV; and [86]).  
Taken together, this project discovered the presence of the FPR2/ALX receptor in EC in 
human atherosclerotic plaques (Paper I). Additionally, Paper IV revealed that lacking Fpr2 
signaling in EC was associated with impairment of proliferation, endothelium dysfunction and a 
decrease in the vascular bed in neonatal hearts (Paper IV). 
5.3 ATL as a possible therapeutic option for CVD 
Given that LXA4 and its analogs are efficient as anti-inflammatory and pro-resolution 
agents, these properties were challenged in this thesis in vitro and in vivo. First, THP-1 cells 
exposed to LXA4 exhibited reduced levels of pro-inflammatory mediators such as IL-8, IL-1, 
CXCL-16 and MMP-9 (Paper III). The present thesis in addition showed that vascular structural 
cells are able to express FPR2/ALX (Paper I) and respond to ATL (Paper II and V). The 
beneficial effects observed when ATL was administered in vitro and in vivo raise the notion of 
ATL as a possible treatment for atherosclerosis and its complications. 
To further support the concept of using ATL to reduce inflammation, the atherosclerosis 
model with ApoE-/- mice expressing and lacking the Fpr2 receptor were treated with ATL. The 
results supported that ATL is able to retard plaque development only in Fpr2 expressing mice, 
along with less macrophages infiltrated to the plaque and lower levels of IL-6 and MMP-13 in 
the aorta, spleen and lung of ATL-treated mice (Paper V). These results are in accordance with 
other studies, which explored Fpr2 signaling with different anti-inflammatory/pro-resolving 
ligands such as Annexin A1. For instance, nanoparticles conjugated with a fragment (Ac2-26) of 
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Annexin A1 were able to increase collagen and reduce atherosclerosis plaque size [108]. 
Additionally, Annexin A1 treatment reduced atherosclerosis in Ldlr-/- mice [130]. Interestingly, 
the treatment with this FPR2/ALX ligand induced no effect after 6 weeks of treatment along with 
HFD, whereas the treatment was effective to reduce plaque size without SMC and macrophages 
changes after 12 weeks of HFD [130]. The therapeutic effect of Fpr2 signaling by pro-resolution 
ligands might have an important role in structural cells. Finally, recent evidence support that 
LXA4-Fpr2 signaling is crucial in reduce leukocyte recruitment in a stroke model [131]. Taken 
together with those previous studies, the results of the present thesis indicate that Fpr2 activation 
by pro-inflammatory ligands may drive the atherosclerosis process but that the treatment with 
anti-inflammatory and pro-resolution Fpr2 ligands may overcome these pro-inflammatory 
properties and exert beneficial effects. These observations open up for ATL as a therapeutic 
option to reduce CVD. 
Vascular injury, such as percutaneous coronary interventions, may lead to intimal 
hyperplasia and restenosis of the vessel. Previous experimental studies have suggested 
therapeutic options of inhibiting pro-inflammatory lipid mediator signaling to prevent intimal 
hyperplasia [47, 67]. The results of Paper II were the first to show that ATL reduced intimal 
hyperplasia in vivo, and that the effects of ATL were abolished in Fpr2 knock-out mice. 
Subsequently, similar results were reported for other pro-resolution lipid mediators [132]. The 
beneficial effects of ATL treatment on intimal hyperplasia could potentially be mediated both 
through direct effects on SMC proliferation and migration (Paper II), but it cannot be excluded 
that also reduced leukocyte recruitment (Paper V) and activation (Paper III) were involved in this 
response. Importantly, the in vitro studies presented in this thesis indicated that Fpr2 deletion 
increased EC proliferation (Paper IV). A decreased SMC proliferation and increased EC 
proliferation would enhance the therapeutic effects of ATL treatment in vascular injury, both 
inhibiting intimal hyperplasia and favoring re-endotheliazation after for example coronary 
angioplasty with stent implantation.   
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6 Conclusions 
 
 
1. In human atherosclerotic lesions, FPR2/ALX is highly expressed and is present on the 
main components of the plaque, such as macrophages, SMC and EC. 
2. Fpr2 signaling promotes atherosclerosis development, as demonstrated in 3 different 
mouse models. 
3. In mouse macrophages, Fpr2 signaling induces a higher inflammatory phenotype. 
4. In mSMC, the lack of Fpr2 signaling induces a higher proliferation and migratory state. 
5. The mSMC migration is reduced by ATL treatment and is Fpr2 dependent. 
6. In mAEC, the deficiency of Fpr2 signaling shows features of endothelial dysfunction and 
lower proliferation rate.   
7. LXA4 acts as anti-inflammatory mediator in THP-1 cells in vitro. 
8. The anti-inflammatory effect of ATL is Fpr2 dependent. 
9. ATL may be a therapeutic option by reducing atherosclerotic lesions and intima 
formation in vascular injury.  
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